Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma

Published:2023-04-25 Issue:5 Volume:43 Page:2119-2126
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

SANO TAKESHI,AIZAWA RIHITO,ITO KATSUHIRO,NAKAMURA KIYONAO,OGATA TAKASHI,TAKEDA MASASHI,HAMADA AKIHIRO,MATSUOKA TAKASHI,KONO JIN,KITA YUKI,MASUI KIMIHIKO,GOTO TAKAYUKI,SAWADA ATSURO,AKAMATSU SHUSUKE,OGAWA OSAMU,MIZOWAKI TAKASHI,KOBAYASHI TAKASHI

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study;Scientific Reports;2024-08-27

2. Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group;Frontiers in Oncology;2024-07-04

3. Bladder Cancer Invading the Prostate and Penis and Multiple Bone Metastases Showing Significant Improvement after a Short-Term Pembrolizumab Therapy following Radiation and Gemcitabine and Cisplatin Therapy Leading to a Pathologically Complete Remission;Case Reports in Urology;2024-05-27

4. Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study;Journal of Clinical Medicine;2023-12-18

5. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18